The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection

Szabo, Shelagh M.; Gooch, Katherine; Bibby, M.; Vo, Pamela; Mitchell, Ian; Bradt, Pamela; Levy, Adrian R.

doi:10.1016/s1526-0542(12)00095-4

Cited by 47 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the data on the rate of inpatient medical care rendering to the control groups at RICU in the RCT of palivizumab efficacy and safety [12,13], we may presume that children would have required RICU care in 13 cases. Given the weighted average rate of lethal outcomes during the severe RSV-associated LRTI hospitalization given in the trial [15], we may have expected 1 death in the group of children under study (tb. 5).…”

Section: Resultsmentioning

confidence: 99%

“…RSV -respiratory syncytial virus, BPD -bronchopulmonary dysplasia, CHD -congenital heart disease. [15]; ** -calculated by multiplying the estimated number of hospitalizations by the rate of lethal outcomes (in %) and rounded to the nearest whole number. RSV -respiratory syncytial virus, LRTI -lower respiratory tract infections, BPDbronchopulmonary dysplasia, CHD -congenital heart disease.…”

Section: Resultsmentioning

confidence: 99%

“…The data on hospital mortality of children with RSV infection are extremely limited, whereas the available values vary significantly [14]. In order to perform our calculations, we used weighted average mortality values obtained as a result of systematic review of 34 trials assessing rate of lethal outcomes depending on the presence of concurrent pathology (prematurity, BPD and CHD) in infants hospitalized due to severe course of the RSV-associated LRTI [15]. The parameters used for modeling outcomes and information sources are given in tb.…”

Section: Methodsmentioning

confidence: 99%

“…2. RSV-associated LRTI mortality in the setting of prematurity 1.1% [15] Note. RSV -respiratory syncytial virus, LRTI -lower respiratory tract infections, RICU -resuscitation and intensive care unit, BPD -bronchopulmonary dysplasia, CHD -congenital heart disease.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

A Clinical and Economical Analysis of the Results Produced by the Program of RSV-Infection Prophylaxis During the Epidemiological Season of 2012/2013 in Moscow

et al. 2013

View full text Add to dashboard Cite

Aleksei Sergeevich Kolbin, PhD, Professor, head of the clinical pharmacology and evidencebased medicine department at the First Pavlov Saint Petersburg State Medical University, Professor of the pharmacology department of the medical faculty at the Saint Petersburg State University Topicality of the issueThe authors touch upon an issue critical for children in neonatality and the first years of lifeimmune prevention of respiratory syncytial virus (RSV) infection [1]. It not only features severe course in the setting of no evidence-based effective and safe etiotropic therapy, but also lays a heavy disease burden (DB) on the society. DB may be numerically represented with a WHO indicator DALY (disability-adjusted life year). This indicator characterizes the disease burden in years of life in relation to disability. In other words, it is equivalent to losing 1 healthy life year. It is known that DALY (Score/1,000) for RS infection is 67.7, whereas for adenovirus it is 49.7, for herpes -34.4, for influenza A -6.8 [2, 3]. RS infection burden is comprised of two main components -high hospitalization frequency in children with RSV and consumption of healthcare resources by children under 2 years of age. At the same time, there are technologies of controlling this medical and social issue -immune prevention of RS infections with monoclonal antibodies. Palivizumab is considered to be such a vaccine. There is evidence (meta-analysis of clinical trials) that immune prevention has reduced mortality more than 4 times in the group of children born before the 32 nd gestation week [4]. Prevention of RS infection is a standard practice in children born before the 30 th gestation week regardless of the economic development level. Unfortunately, the Russian Federation does not partake in this process (unlike, say, Ecuador), although preservation and rehabilitation of children's health is proclaimed the priority of Russian healthcare. Advantages of the articleThe article by V.I. Ignatyeva et al. is set forth according to the traditional scheme of clinical economic analysis (standards of "Clinical economic analysis", general provision of OST 91500.14. . The author substantiates topicality of the issue, scientific novelty and practical implications of the work, defines the aim of the study and lists methods of pharmacoepidemiological and clinical economic analysis. The obtained data were statistically manipulated using difference significance criteria. The study involved detailed analysis of palivizumab immune prevention results in Moscow in the season of 2012/2013. The article features detailed calculation of expenses per 1 disability-adjusted life year and proves that the taken measures prevented economic loss due to infantile mortality decrease. The results demonstrate that use of palivizumab for preventing RS infection ought to be considered clinically and economically sound. The article is a complete scientific study; it is well illustrated, written in the literary language and is rather readable despite complicated nature of ...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

A Clinical and Economical Analysis of the Results Produced by the Program of RSV-Infection Prophylaxis During the Epidemiological Season of 2012/2013 in Moscow

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Çocukluk yaş grubunda en sık bildirilen ASYE etkenleri; respiratuar sinsisyal virüs (RSV), parainfluenza virüs (PIV) influenza virüsleri ve adenovirüslerdir. Bunlardan RSV tüm dünyada özellikle kış aylarında yılda yaklaşık 3.4 milyon 5 yaş altı çocuğun hastaneye yatışına neden olmaktadır [17][18][19].…”

Section: Akut Solunum Yolu Enfeksi̇yonuunclassified

Two Different Complementary Methods In The Treatment Of Children With Acute Respiratory Tract Infection: Massage And Acupressure

Alsaç¹,

Polat²

2017

Spatula DD

View full text Add to dashboard Cite

Acute respiratory tract infections are among the most common childhood diseases and the most important causes of infectious diseasesrelated mortality and morbidity throughout the world. In the treatment of respiratory tract infections, in addition to the medical treatment, several complementary and alternative treatment methods are implemented to relieve and cure the symptoms of a child. In this compilation, information about the effects of massage and acupressure on the improvement of the symptoms of respiratory tract infections is provided. Malnütrisyon, bir yaşın altında olma, tamamlanmayan aşılar, anne sütü ile beslenmeme, düşük doğum ağırlığı, tedavinin etkin bir şekilde yürütülememesi, nüfus yoğunluğu, hava kirliliği, genel hijyen yetersizliği, immobilizasyonla seyreden kronik hastalıklar, sık hastaneye yatış ve nazokomiyal enfeksiyonlar gibi etkenler de ASYE için duyarlılık oluşturmakta ve mortaliteyi artırmaktadır [4,5]. ASYE tedavi edilmediğinde ya da tedaviye zamanında başlanmadığında hastalık kronikleşebilir ya da çeşitli komplikasyonlar görülebilir. Başta respiratuar sinsisyal virüs (RSV) olmak üzere viral enfeksiyonlardan sonra bronş duvarında geri dönüşümsüz anjiyofibröz değişiklikler, tekrarlayan enfeksiyon ve inflamasyonlara bağlı bronşektaziler, pulmoner fibrozis, akciğer apsesi ve ampiyem ASYE'de oluşabilecek komplikasyonlardandır [6,7]. Ayrıca beş yaşın altındaki çocuklarda, sıklıkla viral bir üst solunum yolu enfeksiyonu nedeniyle yüksek ateş görülmektedir. Sıklıkla enfeksiyonun başlangıcındaki bu hızlı ateş yükselişi sırasında febril konvülsiyon meydana gelebilmektedir [8]. Solunum yolu enfeksiyonlarında tıbbi tedavinin yanı sıra, çocuğu rahatlatma ve iyileştirmeye yönelik uygulanan çeşitli tamamlayıcı ve alternatif tedavi (TAT) yöntemleri arasında masaj ve akupresör de önerilmektedir [9]. Yapılan çalışmalarda masaj ve akupresin solunum fonksiyonlarını düzenlediği, sekresyon çıkışını kolaylaştırdığı, oksijen satürasyonunu artırdığı, immün sistemi KEY WORDS:

show abstract

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)

Wang

Li²,

Paes

et al. 2017

Eur J Pediatr

Self Cite

View full text Add to dashboard Cite

Children aged <2 years with chronic lung disease (CLD) have a 10-fold higher risk for respiratory syncytial virus-positive hospitalization (RSVH) compared to healthy term infants. Based on the updated position statements, we compared respiratory-related illness hospitalization (RIH) and RSVH risks in CLD children who received palivizumab during the first year (FY) versus second year (SY) of life in the Canadian Registry of Palivizumab (CARESS). Demographic data were collected at enrolment and RIH events recorded monthly from 2005 to 2015. Eight hundred forty-seven FY and 450 SY children with CLD were identified. SY children had a lower gestational age (27 versus 29 weeks) and required more days of respiratory support (64 versus 43), oxygen therapy (108 versus 55), and length of stay (118 versus 73) during the neonatal course compared to FY children; all p < 0.0005. RIH rates were 12.2 (FY) and 18.2 (SY), and RSVH rates were 2.3 (FY) and 3.9 (SY). Cox regression showed similar hazards for both RIH (hazard ratio 0.9, 95% CI 0.6–1.6, p = 0.812) and RSVH (hazard ratio 1.1, 95% CI 0.4–2.9, p = 0.920). Conclusions: SY and FY children had similar risks for RIH and RSVH. The findings imply that SY children with CLD are correctly selected for palivizumab based on neonatal illness severity and merit prophylaxis. What is Known: • Children with chronic lung disease have a 10-fold higher risk for RSV-positive hospitalization in comparison to healthy term infants and commonly receive palivizumab prophylaxis as a preventative measure against serious RSV-related lower respiratory tract infections. • The American Academy of Pediatrics [ 2 ] and the Canadian Paediatric Society [ 30 ] have recently modified their recommendations for RSV prophylaxis in children with chronic lung disease, limiting palivizumab to either those <32 weeks gestation or those in the first year of life who are oxygen dependent or require medical therapy for the treatment of their condition. What is New: • Children with chronic lung disease receiving an additional course of palivizumab in their second year of life were determined to be at similar risk for both respiratory illness-related hospitalization and RSV-positive hospitalization as palivizumab-naïve children enrolled in the first year of life in the Canadian Registry for palivizumab (CARESS). • CARESS physicians are correctly identifying high-risk children with chronic lung disease in their second year of life, whom they believe will benefit from an additional year of palivizumab prophylaxis, based on neonatal illness severity.

show abstract

The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection

Cited by 47 publications

References 38 publications

A Clinical and Economical Analysis of the Results Produced by the Program of RSV-Infection Prophylaxis During the Epidemiological Season of 2012/2013 in Moscow

A Clinical and Economical Analysis of the Results Produced by the Program of RSV-Infection Prophylaxis During the Epidemiological Season of 2012/2013 in Moscow

Two Different Complementary Methods In The Treatment Of Children With Acute Respiratory Tract Infection: Massage And Acupressure

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)

Contact Info

Product

Resources

About